Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone.
De Deyn
P P
PP
Department of Neurology and Memory Clinic, General Hospital Middelheim and Laboratory of Neurochemistry and Behaviour, University of Antwerp, Universiteitsplein 1, 2020 Antwerp, Belgium. ppdedeyn@uia.ac.be
Katz
I R
IR
D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002170:Canada; D003704:Dementia / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005060:Europe; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
D014150:Antipsychotic Agents; D006220:Haloperidol; D018967:Risperidone